Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Pablo E. Pergola; Matt Devalaraja; Steven Fishbane; Michel Chonchol; Vandana S. Mathur; Mark T. Smith; Larry Lo; Kurt Herzog; Rahul Kakkar; Michael H. Davidson

doi:10.1681/ASN.2020050595

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Visual Abstract

Significance Statement

Patients with CKD who are on hemodialysis are hyporesponsive to erythropoiesis-stimulating agents (ESAs) because of anemia of inflammation mediated by IL-6–induced expression of hepcidin, an iron regulatory hormone. Reducing ESA usage to decrease ESA-related cardiovascular risk, especially with high ESA doses, is a clinical goal of nephrologists. In this randomized, phase 1/2 trial in patients with inflammation on hemodialysis, the authors show that ziltivekimab, a novel anti–IL-6 ligand antibody, reduced markers of inflammation, decreased ESA usage, and increased serum albumin, which might lead to a reduction in overall cardiovascular risk. Because current anemia treatments do not reduce inflammation, the availability of an anti-inflammatory therapy that also improves iron utilization and reduces the need for escalating doses of ESAs could represent an important advancement in the care of patients on hemodialysis.

Abstract

Background Patients with CKD who are on hemodialysis are hyporesponsive to erythropoiesis-stimulating agents (ESAs) because of anemia of inflammation. Interleukin-6 (IL-6) induced hepcidin expression is a key mediator of such inflammation.

Methods This phase 1/2, placebo-controlled trial assessed effects of ziltivekimab, a novel anti–IL-6 ligand antibody, in patients on hemodialysis with rs855791, a single nucleotide polymorphism of the TMPRSS6 gene that is hypothesized to heighten susceptibility to IL-6–mediated inflammatory effects. After a screening period documenting stable ESA and iron dosing, we randomized 61 patients with elevated IL-6 (≥4 pg/ml) to receive placebo or ziltivekimab (doses of 2, 6, or 20 mg), administered intravenously every 2 weeks for 12 weeks during hemodialysis. ESA dose adjustments were allowed after 4 weeks. We analyzed safety and effects on inflammation, iron metabolism, serum albumin, and anti-drug antibodies.

Results No patient experienced dose-limiting toxicity. Four patients (two each in the 6- and 20-mg cohorts) died of a treatment-emergent adverse event. Compared with patients receiving placebo, those receiving ziltivekimab experienced significantly greater reductions of high-sensitivity C-reactive protein, serum amyloid A, and fibrinogen from baseline to end of treatment. Median ESA usage decreased by 15,000, 15,000, or 33,000 IU/wk per patient in the 2-, 6-, and 20-mg ziltivekimab cohorts, respectively, compared with no change in the placebo group. We also noted significant dose responses for decreased ESA resistance index and increased serum iron, total iron binding capacity, transferrin saturation, and serum albumin.

Conclusions Ziltivekimab significantly improved markers of inflammation, reduced ESA requirements, and increased serum albumin in patients on hemodialysis with inflammation and hyporesponsiveness to ESA therapy.

Clinical Trial registry name and registration number Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001, NCT02868229

View Full Text

Log in through your institution

Purchase access

You will have access to the article for 24 hours.

If you do not have an account, you will need to create one and you will be asked for your name, email address and other information. Just like commercial web sites, we do need details from you in order to complete your purchase of an article. Select the "Create an Account" link to create your account.

You will then be asked to register a user name, email address and you will need to create a password that is at least eight characters in length. As you move through the registration page, you will have to verify you are a person by completing a Captcha request. Lastly, your first and last name will be required.

Once your information is successfully saved, the system will redisplay the home page of the journal. From there, navigate back to the article to purchase. Select the article and at the bottom of the page, use the credentials you just created to login. The article will be added to your shopping cart. You can continue to navigate across JASN and CJASN adding to your cart from both journals. When you are ready to complete your purchse, select the Shopping Cart from the upper right hand corner of the page and follow the onscreen instructions.